- Home
- SABS vs FENC Comparison
SABS vs FENC Comparison
Compare SABS & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SABS | FENC |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | 35 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.8M | 350.0M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SABS | FENC |
|---|---|---|
| Price | $2.51 | $9.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | $11.64 | ★ $17.67 |
| AVG Volume (30 Days) | ★ 747.3K | 115.9K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.53 | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $62.55 |
| Revenue Next Year | N/A | $42.10 |
| P/E Ratio | ★ N/A | $172.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.45 | $5.65 |
| 52 Week High | $5.15 | $13.25 |
Technical Indicators
Market Signals| Indicator | SABS | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 27.82 | 40.60 |
| Support Level | N/A | $9.87 |
| Resistance Level | $4.04 | $10.66 |
| Average True Range (ATR) | 0.20 | 0.49 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 12.76 | 12.90 |
Price Performance
Historical ComparisonAbout SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.